Solensia contains frunevetmab. This is a feline monoclonal antibody (mAb) which targets nerve growth factor (NGF). This in turn inhibits NGF mediate cell signalling which helps reduce pain associated with osteoarthritis disorders.

The medication is administered by subcutaneous injection once every 28 days. Solensia is a welcome addition to the veterinary arsenal on fighting pain associated with arthritis and will be particularly useful for cats difficult to medicate on a daily basis.

The product has only just received a positive opinion for initial marketing on the 10th December 2020 so it will be a while before it is released onto the veterinary market. We will provide more information on the product when it becomes available.

If you have any specific questions regarding Solensia please contact our customer services on [email protected].

Written by: Dr. Nick Garside BVetMed MRCVS